Abstract
COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in different clinical manifestations ranging from asymptomatic/mild to severe disease that requires hospitalization. Here, we demonstrated that SARS-CoV-2 infection results in a glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently triggered by a serological factor. This specific glycan switch of T cells is detected at diagnosis being more pronounced in asymptomatic patients. We further demonstrated that asymptomatic patients display an increased expression of a viral-sensing receptor, through the up-regulation of DC-SIGN in monocytes. We showed that higher levels of DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. These new evidences pave the way to the identification of a novel glycan-based response in T cells that may confer protection against SARS-CoV-2 infection in asymptomatic patients, highlighting a novel prognostic biomarker and potential therapeutic target.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Institute of Molecular Pathology and Immunology of the University of Porto integrates the Institute for Research and Innovation in Health (i3S) research unit, which is partially supported by the Portuguese Foundation for Science and Technology (FCT). This article was partially funded by the FCT, in collaboration with the Portuguese Agency for Clinical Research and Biomedical Innovation (AICIB) under the special funding, RESEARCH 4 COVID-19_Project #006 granted to the PI Salomé S. Pinho. IA [SFRH/BD/128874/2017] and MV [PD/BD/135452/2017] 25 received funding from the FCT.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants gave informed consent about all clinical procedures and research protocols were approved by the ethics committee of CHUP and CHVNG, Portugal.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵9 Lead Contact
Grant Support: The Institute of Molecular Pathology and Immunology of the University of Porto integrates the Institute for Research and Innovation in Health (i3S) research unit, which is partially supported by the Portuguese Foundation for Science and Technology (FCT). This article was partially funded by the FCT, in collaboration with the Portuguese Agency for Clinical Research and Biomedical Innovation (AICIB) under the special funding, “RESEARCH 4 COVID-19”_Project #006 granted to the PI Salomé S. Pinho. IA [SFRH/BD/128874/2017] and MV [PD/BD/135452/2017] received funding from the FCT.
Data Availability
Data is not available.
